Uzbekistan, JGL’s New Market With Its Own Operations

On 25 March 2024, JGL opened its representative offices in Uzbekistan, bringing the total number of markets with their own operations to eleven. Expanding the company’s business into a new region is part of our overarching corporate strategy, and JGL is entering Uzbekistan with a portfolio from key therapeutic groups – flu and cold, ophthalmology and dermatology.

“This is a growing market that is opening up to the world, and as a result, it is seeing major changes in consumer behaviour following global trends. Some specific examples include increased internet use, air-conditioned spaces due to the warm and dry climate, and a large number of young mothers and a growing number of children. In light of the above, JGL has a very attractive portfolio, as well as the expertise and experience that can help both in treatment and prevention,” said Alenka Jajac-Knez, Director of Market Operations, adding that Uzbekistan has a population of 36 million and is projected to reach nearly 41 million people by 2040.

“GDP is estimated to increase by 10 per cent per year in the next few years, and a drop in inflation is expected in the same period. The pharmaceutical market is rapidly changing and is very dynamic – it is estimated at USD 1.6 billion and is growing at an annual rate of 6.5%. The reference market with JGL’s key therapeutic groups is growing at double-digit rates,” says Jajac-Knez, concluding that she has no doubt that JGL’s extensive experience of doing business in CIS markets will contribute to a successful brand positioning in the new market, as well as further growth and development of our company.

To make this website run properly and to improve your experience, we use cookies. For more detailed information, please check our Privacy and personal data protection.

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.